Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).

MLA

Yamamoto, N., et al. “Randomised Phase II Study of Docetaxel/Cisplatin vs Docetaxel/Irinotecan in Advanced Non-Small-Cell Lung Cancer: A West Japan Thoracic Oncology Group Study (WJTOG9803).” British Journal of Cancer, vol. 90, no. 1, Jan. 2004, pp. 87–92. EBSCOhost, https://doi.org/10.1038/sj.bjc.6601462.

APA

Yamamoto, N., Fukuoka, M., Negoro, S. I., Nakagawa, K., Saito, H., Matsui, K., Kawahara, M., Senba, H., Takada, Y., Kudoh, S., Nakano, T., Katakami, N., Sugiura, T., Hoso, T., & Ariyoshi, Y. (2004). Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). British Journal of Cancer, 90(1), 87–92. https://doi.org/10.1038/sj.bjc.6601462

Chicago

Yamamoto, N., M. Fukuoka, S.I. Negoro, K. Nakagawa, H. Saito, K. Matsui, M. Kawahara, et al. 2004. “Randomised Phase II Study of Docetaxel/Cisplatin vs Docetaxel/Irinotecan in Advanced Non-Small-Cell Lung Cancer: A West Japan Thoracic Oncology Group Study (WJTOG9803).” British Journal of Cancer 90 (1): 87–92. doi:10.1038/sj.bjc.6601462.